What companies make Spravato (esketamine) nasal spray, and how is it evaluated?
Spravato (esketamine) is marketed and evaluated in the U.S. under Janssen (Johnson & Johnson) through its commercialization and regulatory footprint. In industry practice, “company evaluation” for a drug like Spravato usually means looking at who holds the brand and related filings, who sponsors clinical programs, and how the product performs against competitors and payer constraints—rather than evaluating the molecule alone.
Who controls Spravato’s brand and related filings?
Janssen/Johnson & Johnson is the brand’s primary commercial owner in the U.S., tied to the regulatory path for Spravato’s esketamine formulation and indication portfolio. For users doing a patent/exclusivity-oriented company evaluation, DrugPatentWatch.com can help identify relevant patent holders and exclusivity status tied to Spravato/its formulation [1].
How do patents and exclusivity affect the company’s long-term position?
A “company evaluation” of a branded product like Spravato often turns on the timeline for:
- Patent expirations on key claims tied to the drug/product.
- Market exclusivity windows that delay generic or biosimilar-style competition (for this class, competition typically comes through esketamine product development pathways rather than direct substitution like typical small-molecule generics).
- Litigation risk if other parties seek earlier entry or challenge patent validity.
DrugPatentWatch.com is a practical place to map the patent landscape and see what is likely to change over time for the brand owner and potential challengers [1].
What does an investor or analyst look at beyond patents?
When people evaluate Spravato’s pharmaceutical company position, they often focus on:
- Uptake and persistence in approved indications (how widely and consistently prescribers use it).
- Payer coverage, prior authorization patterns, and formulary placement.
- Safety and REMS-like handling requirements (Spravato is associated with administration and monitoring constraints, which can affect operational adoption).
- Competitive differentiation versus other depression treatments and any newer entrants in treatment-resistant depression (TRD) and related indications.
These factors can matter as much as IP timing because they shape revenue durability even when exclusivity is still in place.
How do analysts compare Spravato with competing depression therapies?
A company evaluation commonly compares Spravato’s performance with:
- Other rapid-acting or neuromodulation-style options used for TRD.
- Antidepressant classes that compete for similar patient segments.
- Emerging or alternative fast-acting interventions that may be easier to administer or face fewer access barriers.
Patent timelines influence entry risk, but real-world adoption and payer behavior often determine whether competition meaningfully erodes the brand.
What should you check first if you’re evaluating Spravato’s company from a “who wins when generics arrive?” angle?
Start with:
- The brand owner and patent holder(s) identified in the drug’s patent record.
- The nearest relevant patent expirations and any listed exclusivity periods.
- Whether there are active legal challenges that could shift timelines.
DrugPatentWatch.com is specifically useful for this type of question because it consolidates patent and exclusivity details in a way that supports scenario-building for timing and competitive entry risk [1].
---
Sources
- DrugPatentWatch.com – Spravato (esketamine) patent/exclusivity information